Opendata, web and dolomites

InterTAU SIGNED

Integrative structural biology of pathological tau protein, an appealing therapeutic target for Alzheimer´s disease modifying drugs

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 InterTAU project word cloud

Explore the words cloud of the InterTAU project. It provides you a very rough idea of what is the project "InterTAU" about.

medical    pharma    oligomeric    relates    expertise    innovation    solid    anti    therapies    structural    bioinformatics    mutual    conformational    solution    nuclear    resonance    unmet    cellular    academic    corroborated    modifying    enormous    pathological    america    hampered    toxicity    altered    complementary    disease    tau    nmr    assembled    lacking    prevention    microscopy    transfer    efficient    intertau    cutting    inducers    tauopathies    diagnosis    transferred    functional    biotech    biophysical    pursuing    alzheimer    stage    sharing    foundation    ing    company    magnetic    denominator    envisaged    platform    oligomerization    immunotherapy    course    sustainable    there    characterization    variants    electron    north    cryo    suitable    pharmacological    forms    outcome    assembly    edge    assays    fibrillar    therapy    deeper    conformationally    ad    molecular    pathology    cooperation    pathogenesis    argentina    clinical    monomeric    translated    protein    biotechnological   

Project "InterTAU" data sheet

The following table provides information about the project.

Coordinator
Masarykova univerzita 

Organization address
address: Zerotinovo namesti 9
city: BRNO STRED
postcode: 60177
website: http://www.muni.cz

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Czech Republic [CZ]
 Total cost 1˙062˙600 €
 EC max contribution 1˙058˙000 € (100%)
 Programme 1. H2020-EU.1.3.3. (Stimulating innovation by means of cross-fertilisation of knowledge)
 Code Call H2020-MSCA-RISE-2019
 Funding Scheme MSCA-RISE
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2023-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    Masarykova univerzita CZ (BRNO STRED) coordinator 441˙600.00
2    AXON NEUROSCIENCE R&D SERVICES SE SK (BRATISLAVA) participant 464˙600.00
3    LATVIJAS ORGANISKAS SINTEZES INSTITUTS LV (RIGA) participant 128˙800.00
4    ROYAL COLLEGE OF SURGEONS IN IRELAND IE (DUBLIN) participant 23˙000.00
5    OREGON STATE UNIVERSITY US (CORVALLIS) partner 0.00
6    UNIVERSIDAD NACIONAL DE CUYO AR (MENDOZA) partner 0.00
7    UNIVERSITY HEALTH NETWORK CA (TORONTO) partner 0.00
8    UNIVERSITY OF PITTSBURGH US (PITTSBURGH) partner 0.00

Map

 Project objective

There is an enormous and unmet medical need to find efficient methods of prevention, diagnosis and disease-modifying therapies for tauopathies, including Alzheimer’s disease. The common molecular denominator of tauopathies are pathological forms of tau protein. Tau pathology relates to conformational changes during oligomerization and assembly resulting in toxicity. Given its role in the pathogenesis, conformationally altered and assembled tau would be a promising molecular target for disease-modifying therapy. However, the field is still lacking a deeper understanding of tau structural changes in the course of assembly and their inducers on the pathway towards the pathological forms of Tau; therefore, the pharma development is hampered. The main aim of the InterTau project is the detailed structural and biophysical characterization of tau protein and its variants in monomeric, oligomeric and fibrillar states relevant for AD and other tauopathies. The InterTAU consortium is composed of a clinical-stage biotech company pursuing development of anti-tau immunotherapy and academic partners with cutting-edge methodologies suitable for functional and structural characterization of the tau assembly pathway by solution and solid-state nuclear magnetic resonance (NMR), cryo-electron microscopy and cellular assays corroborated by bioinformatics. The mutual transfer of complementary expertise envisaged in the project will facilitate academic outcome and biotechnological development. Specific expertise will be transferred from three institutions in North America and one institution from Argentina. The results of InterTAU will be directly translated into innovation in pharmacological development through the non-academic partner. The platform for sharing knowledge will be a foundation of sustainable cooperation beyond the InterTau project.

 Deliverables

List of deliverables.
Project website Websites, patent fillings, videos etc. 2020-04-03 12:46:44

Take a look to the deliverables list in detail:  detailed list of InterTAU deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "INTERTAU" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "INTERTAU" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.3.)

CONMECH (2019)

Nonsmooth Contact Dynamics

Read More  

MAIL (2019)

Identifying Marginal Lands in Europe and strengthening their contribution potentialities in a CO2sequestration strategy

Read More  

ENDORSE (2018)

Safe, Efficient and Integrated Indoor Robotic Fleet for Logistic Applications in Healthcare and Commercial Spaces

Read More